{
  "docId": "019de075-dd1e-7468-9323-d12fde1b7732",
  "docSlug": "a9cc0c508d45d8985f57408ace49b969",
  "documentTitle": "RayzeBio | IPO Presentation Deck | 41 slides",
  "authorId": "rayzebio",
  "authorName": "RayzeBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 18,
  "pageCount": 41,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 21,
  "notes": "Waterfall plot displays individual patient responses; benchmarking table compares ORR against historical standards.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/18",
  "deckHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732",
  "deckJsonHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json",
  "deckAnchorHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.11,
        "w": 0.28,
        "x": 0.68,
        "y": 0.24
      },
      "kind": "callout",
      "text": "5 of 17 patients enrolled (29%) have confirmed objective response per RECIST v1.1",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7dad3ab1-1150-4801-9716-77da87ad5e91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.6,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Max % Change from Baseline, by Investigator",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af210d65-4863-4d71-81ab-ad89fe7f9d0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1As of June 30, 2023, by investigator assessment. 2Based on pivotal studies, patients were radiotherapy naïve.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31138838-9ec9-406e-b798-cb07d8b06a4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.1,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Efficacy evaluable population are those subjects who received at least one RYZ101 dose and had at least one efficacy evaluable assessment.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f1efb6c-4e94-4122-a8f8-238cda7bebd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.68,
        "y": 0.44
      },
      "kind": "table",
      "text": "Benchmarking ORR: Lutathera 13%, Sunitinib 9%, Everolimus 5%, Octreotide LAR 3%",
      "attrs": null,
      "subkind": "kpi",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3afacd81-4e5f-4d1a-8abe-5e723ef17c31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Phase 1b Preliminary Response Analysis – Best Response",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ae4efd3-feed-45df-b201-1cd7f0913c7d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "waterfall-plot",
      "slug": null,
      "matchId": "9576f9cf-fea9-43f0-831d-194cfbdf36c3",
      "evidence": "Standard clinical trial efficacy visualization",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 16,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5",
      "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.",
      "position": 2,
      "objective": "How does RYZ101 perform in clinical trials?",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.7,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}